© 2022 American College of Medical Genetics and Genomics. All rights reserved.
Genetics101 for Healthcare Providers
Date of Release: 2/1/2022
Expiration Date: 2/1/2025
Credits offered: .5 per module
Estimate time of completion: 5 hours
Course/Module must be completed by the expiration date
This course is supported by an independent medical education grant from Illumina, Inc.
This course is primarily for the non-geneticist health care professional.
The American College of Medical Genetics and Genomics is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement: The American College of Medical Genetics and Genomics designates this online enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Accredited Continuing Education Financial Disclosure
The American College of Medical Genetics and Genomics (ACMG) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Accredited Continuing Education (ACE) for physicians. ACMG is an organization committed to improvement of patient care and general health by the incorporation of genetics and genomics into clinical practice.
ACMG has implemented the following procedures to ensure the independence of ACE activities from commercial influence/promotional bias, the Accreditation Council for Continuing Medical Education (ACCME) requires that providers (ACMG) must be able to demonstrate that: 1) everyone in a position to control the content of an ACE activity has disclosed all financial relationships that they have had in the past 24 months with ineligible* companies; 2) ACMG has implemented a mechanism to mitigate relevant financial relationships; and 3) all relevant financial relationships with ineligible companies are disclosed to the learners before the beginning of the educational activity. The learners must also be informed if no relevant financial relationships exist.
*Ineligible companies are defined as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
ACMG Education Policies
Please review the policies below regarding the ACMG Education program
• Financial Disclosures and Mitigation Procedure
• ACMG Content Validation Policy
• ACMG Content Branding Policy
Financial Support Disclosure Statement: The following course director, program planning committee members, speakers, and staff for this activity, have no financial relationships with ineligible companies relevant to the content of this course.
Anne O'Donnell-Luria, MD, PhD, FACMG
Broad Institute of MIT and Harvard
Boston Children's Hospital
Nothing to disclose
Anne O'Donnell-Luria, MD, PhD, FACMG
Boston Children's Hospital, Broad Institute of MIT and Harvard, and Harvard Medical School
Anne O'Donnell-Luria is an Assistant Professor in Pediatrics at Harvard Medical School who leads a research group at Boston Children's Hospital and the Broad Institute of MIT and Harvard. She completed her M.D./Ph.D. training at Columbia University Medical Center followed by the Five-Year Boston Children's Hospital and Harvard Medical School Combined Pediatrics-Genetics Residency Program, an additional year of clinical training in medical biochemical genetics, and postdoctoral training in the MacArthur laboratory at the Broad Institute. Her group research focuses on using large-scale genomic and transcriptomic approaches to increase the rate of rare disease diagnosis through improving rare variant interpretation, empowering the discovery of novel disease genes, and understanding the mechanisms of incomplete penetrance. With Heidi Rehm, she co-leads the Broad Center for Mendelian Genomics and the Rare Genomes Project focused on discovering novel disease genes. She is also a practicing clinician who runs the EpiChroma Clinic at Boston Children's Hospital (BCH) focused on evaluating families with Mendelian chromatin disorders and neurodevelopmental conditions.
In December of 2021, this continuing medical education online enduring activity was reviewed by Drs. Shweta Dhar and Fuki Hisama. To ensure the continued scientific relevance of this enduring material, its content will be reviewed again prior to the expiry date.
ACMG educational programs are designed primarily as an educational tool for health care providers who wish to increase their understanding of the application of genomic technologies to patient care. The ACMG does not endorse or recommend the use of this educational program to make patient diagnoses, particular by individuals not trained in medical genetics. Adherence to the information provided in these programs does not necessarily ensure a successful diagnostic outcome. The program should not be considered inclusive of all proper procedures and or exclusive of other procedures and that are reasonably directed at obtaining the same results. In determining the propriety of any specific procedure or, a healthcare provider should apply his or her own professional judgment to the specific clinical circumstances presented by the individual patient or specimen.
Questions regarding CE credit should be directed to firstname.lastname@example.org